GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prescient Therapeutics Ltd (ASX:PTX) » Definitions » Short-Term Debt

Prescient Therapeutics (ASX:PTX) Short-Term Debt : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 1986. Start your Free Trial

What is Prescient Therapeutics Short-Term Debt?

Prescient Therapeutics's Short-Term Debt for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Prescient Therapeutics's annual Short-Term Debt declined from Jun. 2021 (A$0.17 Mil) to Jun. 2022 (A$0.00 Mil) but then stayed the same from Jun. 2022 (A$0.00 Mil) to Jun. 2023 (A$0.00 Mil).


Prescient Therapeutics Short-Term Debt Historical Data

The historical data trend for Prescient Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prescient Therapeutics Short-Term Debt Chart

Prescient Therapeutics Annual Data
Trend Jun13 Jun14 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.16 0.17 - -

Prescient Therapeutics Semi-Annual Data
Dec13 Jun14 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Prescient Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Prescient Therapeutics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Prescient Therapeutics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Prescient Therapeutics (ASX:PTX) Business Description

Traded in Other Exchanges
N/A
Address
Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.

Prescient Therapeutics (ASX:PTX) Headlines

No Headlines